Omaveloxolone
Friedreich Ataxia
BiogenSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Friedreich Ataxia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idebenone Santhera Pharmaceuticals | Phase 3 | A |
Interferon Γ-1B Amgen | Phase 3 | BB |
rt001 Biojiva LLC | Phase 3 | BB |
Trans-Resveratrol Murdoch Childrens Research Institute | Phase 2 | BB |
CITALOPRAM University of Colorado, Denver | Phase 4 | BB |
View all 38 →
Same molecule, other indications
Omaveloxolone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →